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Abstract
 .Binding and localization of the vasodilator and antitumor drug coactivator dipyridamole DIP and one of its derivatives,
 .  .RA25, to phospholipid vesicles of DMPC dimyristoylphosphatidylcholine and DPPC dipalmitoylphosphatidylcholine
was studied using fluorescence spectroscopy as well as quenching of fluorescence. The analysis of fluorescence data
indicates that neutral dipyridamole binds to the phospholipids in their liquid crystalline phase with an association constant of
950 My1 and 1150 My1 to DMPC and DPPC, respectively. Protonation of DIP leads to a 3-fold reduction of the
 .association constant. For the gel phospholipid phase, the binding is smaller a factor of 2 , independently of pH, suggesting
that the more flexible lipid packing in the liquid crystalline phase facilitates the binding of the drug. The association
constant of RA25 neutral form is considerably lower than for DIP, being around 295 My1. Fluorescence quenching with
nitroxides TEMPO and stearic acid doxyl derivatives suggests the localization of DIP to be closer to the 5th carbon of alkyl
chain. The quenching effect of 5-DSA below the lipid phase transition suggests that a strong static quenching may be
operative. The quenching effect of 16-DSA is almost as great as that for 5-DSA below the phase transition, being even
higher above the phase transition. This effect is probably due to the trans-gauche isomerization of the stearic acid nitroxide,
making the encounter of its paramagnetic fragment with the DIP chromophore possible. Our data are consistent with DIP
location close to the bilayer surface in the border of hydrophobic-polar heads interface which is similar to the data in
micellar systems. In the case of RA25, the drug is in the outer part of the head group interface being much exposed to the
aqueous phase and being significantly less accessible to the membrane nitroxide quenchers. q 1997 Elsevier Science B.V.
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1. Introduction
Biological membranes are extremely complex
structures that require models of much less complex-
ity to investigate different aspects of essential bilayer
w xproperties and functions 1 . The structural frame-
work of the membrane is formed by a lipid bilayer:
two parallel monolayers with their headgroups on the
w xoutside surfaces and their tails pointing inwards 2 .
Lipid vesicles have been used as membrane model
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systems for analysing protein–lipid or drug–mem-
w xbrane interactions 3 . Vesicles are becoming impor-
tant systems to study various physicochemical prop-
erties or biological phenomena and they may be used
w xas carriers for drug delivery 4,5 . Similar to the
micellar systems, vesicles have the ability to solubi-
lize compounds that may be localized in different
 .regions of the bilayer: a in the hydrophobic core;
 .  .b at the headgroups region; or c in the inner or
w xouter aqueous phases 6,7 .
Physical properties of vesicles have been investi-
gated in some detail considering the molecular orga-
nization of the alkyl chain in the hydrophobic core of
w xthe bilayer 1 . These systems may experience a
 .phase transition with a characteristic temperature T ,c
which reflects the degree of the chain packing in the
w xbilayer 6,8,9 . The changes in the phospholipid phase
state upon their transition are believed to affect mem-
brane function by changing the structure andror the
w xactivity of membrane-associated protein 10 . Re-
cently, much work has been done on the perturbation
of the membrane lipid ordering by association of
w xforeign molecules, particularly drugs 11–13 . If these
compounds possess hydrophobic groups that facilitate
and promote the binding to biological membranes,
this may affect the fluidity of the bilayer altering the
phase transition. The drug may introduce a charge
into the membrane leading to a change in its function
w x14 . The site of the drug location within the lipid
moiety is of importance since it relates to the prob-
lem of mediation of the drug action either through
binding to the membrane proteins or modifications
promoted in the lipid structure.
 .Dipyridamole, 2,6-bis diethanolamino -4,8-di-
w x  .piperidino-pyrimido- 5,4-d pyrimidine DIP , has
been used in medicine as a coronary vasodilator and
w xas a coactivator of antitumor compounds 15,16 . The
 .biological activity of DIP and its derivatives de-
pends upon the nature of the substituents in different
w xpositions of the molecule 17–19 . Since DIP struc-
ture presents a pyrimido-pyrimidine nucleus it can be
protonated and exist in solutions in neutral andror
charged forms. The pyrimido-pyrimidine nucleus is
also responsible for the fluorescence properties of the
drug. The fluorescence properties depend signifi-
 .cantly on drug forms neutral or protonated and on
w xthe characteristics of the environment 20 .
In previous work, we have studied the interaction
of DIP with different micelles and lipid monolayers
w x20–24 . It was shown that the molecular mecha-
nisms of DIP interaction imply both non-polar and
polar interactions with these systems. It was con-
cluded that the polarizable heteroaromatic cycle of
DIP is located at the border of polar heads and
hydrophobic tails, while its hydrophobic side groups
are oriented towards the hydrophobic phase. The
results obtained show that these interactions depend
on the surfactant headgroups and the pH of the
medium. In the case of micelles, the effect of the
microheterogeneous environment upon the optical
properties of the drug was assessed and binding
constants and drug localization were obtained. On the
other hand, the studies with monolayers allowed the
effect of the drug upon the properties of the lipid,
such as packing and electric surface potential, to be
assessed. The presence of the drug in the monolayer
induced a condensation as monitored by pressure-area
isotherms.
DIP has also been reported to have quite signifi-
cant antioxidant activity both in model and natural
w xmembrane systems 19,25 . This is a strong indication
of the importance of DIP–membrane interaction in
the mediation of its biological activity.
In the present work, the interaction of DIP with the
zwitterionic lipids dipalmitoylphosphatidylcholine
 .  .DPPC and dimyristoylphosphatidylcholine DMPC
was investigated. The aim of this study is to use a
more realistic membrane model system as compared
w xto previously used micelles 20–23 and to further
elucidate the effect of drug–membrane interaction in
order to obtain a better understanding of the mecha-
nisms of drug action in the organism. DIP–vesicle
interaction is analyzed by fluorescence studies in-
volving both association of the drug to vesicles and
quenching of the fluorescence by quenchers at differ-
ent depth of the bilayer, which allow the localization
of the drug to be obtained.
2. Experimental section
 .Dipalmitoylphosphatidylcholine DPPC , dimyris-
 .toylphosphatidylcholine DMPC , dipalmitoylphos-
 .phatidylglycerol DPPG , lysophosphatidylcholine
 .  .LPC and dipyridamole DIP were purchased from
Sigma. RA25 was a kind gift from Dr. Karl Thomae
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 .GmbH Biberach am Riss, Germany . The fluores-
cence quenchers TEMPO 2,2,6,6-tetramethylpiperi-
.dine-1-oxyl radical and spin labeled stearic acids
with the nitroxide groups at different carbon atoms of
the chain, 5-DSA, 12-DSA and 16-DSA, were pur-
chased from Aldrich. These reagents were used with-
out further purification. All the solutions were pre-
pared in ultrapure water from a Millipore system and
all the other solvents were analytical grade.
In fluorescence measurements, solutions of DIP
were prepared in ultrapure water or in appropriate
 .buffers 0.02 M . The concentrations in phosphate
 .  .pH 7 and 8 and acetate pH 4 buffers were 1.1=
10y5 M. The experiments were performed at temper-
atures below and above the phase transitions of the
 . w xlipids 238C for DMPC and 418C for DPPC 8 .
The pH titrations were carried out in water using
HCl or NaOH concentrated stock solutions. The sus-
pension of vesicles containing the drug was added to
the fluorescence cuvette and then, small aliquots of
acid or base were added directly to the cuvette and
the emission intensities were monitored as a function
of the pH.
Binding constants were obtained by titrations of
the drug solutions in appropriate buffers and pHs.
These experiments were performed by additions of
 .aliquots of vesicle or micelle concentrated stock
 .solutions 5 mM to the solution of the drug, directly
to the fluorescence cuvette, and the emission intensi-
ties were registered after each addition. Data were
w xanalyzed as described previously 20,21,23 .
In the determination of binding constants and pKa
value, DIP was excited at 415 nm and the emission
was monitored at 460 nm, the wavelength where the
maximal changes were observed in the presence of
saturating lipid.
The fluorescence quenching experiments of the
drug were performed in the presence of vesicles
using as quenchers sodium iodide, the nitroxide radi-
cal TEMPO 2,2,6,6-tetramethylpiperidine-1-oxyl
.radical or the spin labeled stearic acids with the
nitroxide groups at different carbon atoms of the
 .chain 5-DSA, 12-DSA and 16-DSA . Aliquots of
 .concentrated solutions of the quenchers 10 mM
were added directly to the drugrvesicle solution
 .with saturating amount of lipid contained in the
fluorescence cuvette and the fluorescence intensities
were monitored at maximum emission wavelength
 .485 nm ; data were analyzed by Stern–Volmer plots
w x26 .
Fluorescence measurements were performed on a
Perkin–Elmer LS-5B spectrofluorometer equipped
 .with a thermostated bath Fischer 801 , the absorp-
tion was monitored on a Hitachi U-3000 spectro-
photometer. The pH values were measured with a
Corning 130 pH meter equipped with a glass
AgrAgCl semimicro combination electrode.
2.1. Vesicle preparation
The lipids were dissolved in chloroform and the
solvent was removed with a stream of nitrogen and
then under vacuum at room temperature. The disper-
sion was prepared by the addition of an appropriate
aqueous buffer solution, followed by shaking in a
Vortex. The lipids were left to hydrate for 2 h at a
temperature above the phase transition temperature.
Then the suspension of unilamellar vesicles was pre-
pared by the extrusion technique through polycarbon-
 .ate filters Nucleopore with 0.1 mm pore size, using
a Lipex Extruder. The vesicles were extruded through
the two filters ten times at a temperature above the
w xphase transition 27 . All fluorescence experiments
were performed immediately after vesicle preparation
to avoid sample deterioration. The size of the vesicles
was monitored by light scattering and was shown to
be uniformly distributed as a single peak around 0.11
w xmm, very close to the pore size of the filter 28,29 .
3. Results and discussion
3.1. Spectral properties in the presence of
phospholipids
Spectral properties of dipyridamole have been ex-
w x ) )tensively studied 20–23 , p“p and p⁄p
transitions in the heteroaromatic cycle are responsible
for the optical absorption DIP shows absorption
.bands with maxima around 280 and 410 nm and for
the intense emission of fluorescence, centered around
w x500 nm 20–23 . The quantum yield of DIP fluores-
 .cence is high in neutral solution pH 7.0 , but the
solubility is low at this pH; in acid solutions the
solubility increases, but the quantum yield is reduced
w x20 . In Fig. 1, the fluorometric titration of a mixture
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Fig. 1. Dependence of emission intensity of DIP in aqueous
solutions in the presence of DMPC as a function of pH. Excita-
tion wavelength 415 nm, emission wavelength 460 nm. Concen-
trations: DIP, 1=10y5 M; and DMPC, 2=10y3 M.
of DIP and DMPC vesicles at fixed concentrations is
shown, in which the dependence of DIP emission
intensity on the medium pH is observed. The emis-
sion intensities obtained as a function of pH were
treated using the equation of Henderson–Hasselbach,
w xdescribed in a previous paper 30 , and the titration
Fig. 2. Fluorescence emission spectra of DIP in aqueous solution
 .pH 7 in the absence yPyPy and in the presence of DMPC
 . vesicles . Concentrations of DMPC are in order of
.increasing intensity, in mM : 0.146, 0.239, 0.414, 0.654, 1.16 and
1.96. Concentration of DIP, 1=10y5 M; excitation wavelength,
415 nm.
curve was fitted using this equation in order to obtain
the pK value.a
In the presence of the vesicles the pK obtaineda
for DIP was 5.30"0.02. This value is lower than the
w xvalue for DIP in water, which is 5.8 20,23 . The
change in pK gives evidence of the interaction ofa
the drug with the phospholipid membrane. This value
is higher than that obtained for zwitterionic micelles
 . w x4.3 for HPS 20,23 suggesting a more superficial
localization of the drug in the lipids.
The binding constants of DIP to vesicles were
determined by the titration method in which the
vesicle concentration is varied at constant drug con-
centration. In Fig. 2, the emission spectra of DIP are
presented as a function of DMPC concentration. The
maximum emission wavelength is shifted to the blue
denoting the effective localization of the drug in an
hydrophobic environment, with a gradual increase in
the fluorescence intensity.
3.2. Binding constants to phospholipids
Considering the equilibrium:
DqL¡DyL 1 .
where D represents the drug and L the studied lipid,
the total fluorescence observed is due to the free and
bound species of D. DF represents the difference
between the fluorescence emission intensity of the
 .drug at a certain concentration of the lipid F and
 .the initial fluorescence intensity F8 , in the absence
 .of the lipid. This difference DF is related to the
quantity of the drug associated with the lipid.
In order to obtain quantitatively the association
constants for binding of DIP to phospholipid vesicles,
data for titrations of the drug with phospholipid were
w xtreated using the mass-action law 23 and by the
w xmethod of the double reciprocal plot 21,23 . This
latter treatment is based on the following equation:
1 1 1 1 1
s q 2 .
DF DF DF K Lmax max b
w xA plot of 1rDF as a function of 1r L may be used
to find K , the binding constant. The results obtainedb
for both treatments are listed in Table 1. Some typical
results of these titrations are presented in Figs. 3 and
4. Fig. 3 presents the binding of DIP to DPPC above
 .the phase transition temperature 508C at several
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Table 1
Binding constants of dipyridamole in phospholipid vesicles at
different pH values and temperatures, calculated by the method
 .  .of the double reciprocal plot a and by the mass-action law b
 .  .pH T a K K b Kb d b
y1 y3 y1 .  .  .  .8C M 10 M M
DMPC 7 30 951"22 1.06"0.04 943
8 30 1090"60 0.94"0.02 1064
DPPC 4 30 195"60 y y
50 424"77 y y
7 30 633"22 1.52"0.08 658
50 1149"16 0.85"0.02 1176
8 30 694"19 1.44"0.06 694
50 1302"16 0.76"0.02 1316
DPPCqDPPG 7 30 460"22 2.04"0.09 490
 .11%
50 828"19 1.15"0.02 869
LPC 7 30 5380"260 0.18"0.01 5530
50 4350"130 0.23"0.01 4340
pHs, while Fig. 4 corresponds to the same data
presented as double reciprocal plots.
For DMPC and deprotonated DIP above the transi-
3 y1 tion temperature, K is around 1=10 M Tableb
.1 , a value similar to those found for SDS and HPS
w xmicelles 20 . At pH 8.0 K increases around 15% asb
compared to pH 7.0. The values obtained from both
Fig. 3. Change in the fluorescence emission of DIP in the
presence of DPPC vesicles at 508C. ’, pH 4.0; v, pH 7.0; and
B, pH 8.0. The full lines are the fits to the experimental data.
Concentration of DIP, 1=10y5 M; excitation at 415 nm and
emission at 460 nm.
Fig. 4. Double reciprocal plot of the change in the fluorescence
emission vs. concentration of DPPC for DIP at 508C. ’, pH 4;
v, pH 7.0; and B, pH 8.0. The full lines are the fits to the
experimental data. Concentration of DIP, excitation and emission
wavelengths are the same as in Fig. 3.
treatments of data, direct fitting of binding isotherm
or double reciprocal plot, are very similar. In the case
of DPPC, measurements were performed both above
and below the lipid phase transition and at different
pH values. It is seen that at all studied pHs, the value
of K is by a factor of 1.8–2.2 greater above theb
phase transition. Comparison of K for DIP in DPPCb
at pH 7.0 and 8.0 shows an increase around 14% at
pH 8.0, similar to the result with DMPC. At pH 4.0,
where the drug is protonated, the association constant
to DPPC is reduced by a factor of 3 as compared to
pH 8.0. So, the neutral drug has an association
constant greater than the protonated one, this result
being similar to that found previously for micellar
w xsystems 20 , suggesting that an electrostatic interac-
tion occurs between the phospholipid headgroup and
the protonated form of DIP, making the association
w xunfavorable 23 . The protonation also reduces the
drug affinity to the hydrophobic portion of the mem-
brane, leading to an increase in the drug solubility in
the water phase. This fact was observed previously
w xfor zwitterionic HPS micelles 22,23 . In the micelle
the reduction of K is considerably greater than inb
the vesicle consistent with a greater change in pK ofa
w xthe drug 23 .
In the case of the neutral drug, the values of K b
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 .for DPPC are similar 20% higher to those obtained
for DMPC, but they are lower than those obtained for
 .LPC by a factor of 3.8 , where the binding is more
effective. Binding constants to phospholipid vesicles
tend to increase as a function of temperature, this fact
 .being due to the transition of an ordered rigid gel
phase to a liquid crystalline phase, where the chains
become more disordered and so the packing is not so
w xdense 6,8,9 . Above the phase transition temperature,
the bilayer is more fluid and this effect promotes the
increase in partitioning of the drug in the bilayer.
This fact is clearly observed for the DPPC system
and it is not so obvious for DMPC, probably due to
the relatively low transition temperature for the latter
 .around 238C which would require experiments at
lower temperatures. This effect was not observed in
LPC micelles where the K value only decreasesb
with temperature increase decrease of 19% at the
.higher temperature . The higher value of K and itsb
weak temperature dependence for LPC as compared
to DPPC is probably related to the more dense pack-
ing of the lipids in the bilayer which leads to a
reduction in binding constant for the drug due to the
restrictions imposed on its accommodation in the
bilayer. In the more flexible micellar system, the
association is facilitated and the binding constant is
significantly higher. These results are also in agree-
ment with the changes in pK for the drug, which area
much smaller in the phospholipid system as com-
pared to the micelles. This is also consistent with the
fact that the polarity of both systems, LPC and
DPPC, as monitored by ESR spectra of 5-DSA is
quite similar the isotropic hyperfine constants are the
.same .
A preliminary experiment was also performed to
check if the surface charge in the membrane affects
the binding of the drug. A mixture of DPPC and
 .DPPG 11% at pH 7.0 was used, and the results
obtained suggest that the negative charge in the bi-
layer or the change in the lipid packing leads to a
reduction of the association constant for neutral DIP
of around 28%. Studies of interaction of DIP with
phospholipid monolayers have shown that at low
concentrations of neutral drug, a condensation of the
monolayer is observed both for DPPC and DPPG. A
higher surface pressure is required for the coexistence
of liquid expanded and liquid condensed phases and
w xthis increase is greater in DPPC 31 . Despite the
difficulties in directly comparing the data on mono-
layers with those in vesicles, we believe the reduction
in K could be due to a more dense lipid packing inb
the mixture of DPPCrDPPG since the effect of the
neutral drug is quite similar for both phospholipids.
This increase in packing is also supported by the shift
of the phase transition temperature to higher values
 .  .458C observed for DPPC and DPG 12% mixtures
w x32 .
3.3. Binding of RA25 deri˝ati˝e
In order to compare the values of association
constants, a DIP derivative, RA25, was used. This
compound is known to be considerably more soluble
in water than DIP and to associate to a less extent to
w xmicelles 20 . Besides this, its biological activity is
w xlower than that of DIP 17–19 . Data for binding
constants of RA25 are presented in Table 2. It is
clearly seen that the constant is reduced from around
y1  . y11150 M for DIP Table 1 to around 295 M for
RA25 at pH 7.0, a trend similar to that observed for
w xmicelles 20 . In this case, no pH effect on K isb
observed, the values being the same within the exper-
imental error for all pH values. The side substituents
determine the hydrophobic properties of the DIP
derivative molecules and, hence, their interaction with
the lipid system are probably related to their biologi-
w xcal activity 18,19 . For RA25, the solubility in the
aqueous phase is quite significant in the explored pH
range consistent with a lower solubility in the mem-
w xbrane and a lower activity 17–19 . So, our data are
in agreement with the previous results of interaction
of the drug with micelles and our proposal that the
biological activity correlates with membrane solubil-
ity.
Table 2
Binding constants of RA25 in phospholipid vesicles at 508C and
different pH values, calculated by the method of the double
 .  .reciprocal plot a and by the mass-action law b
 .  .pH a K K b Kb d b
y1 y3 y1 .  .  .M 10 M M
DPPC 4 306"107 5.58"2.00 179
7 295"70 4.32"1.12 232
8 267"56 3.46"0.36 289
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3.4. Fluorescence quenching in phospholipids
Fluorescence quenching studies may be employed
to investigate the position of the drugs in a bilayer.
The fluorescence quenching of DIP was analyzed
using different quenchers, like I -, TEMPO and com-
pounds with a nitroxide radical at a shallow, medium
or deep location in the bilayer. Solutions of the drug
saturated with lipids were monitored by their fluores-
cence emission as a function of quencher concentra-
tion. In Figs. 5 and 6 Stern–Volmer plots obtained in
typical experiments are shown. The plots are linear in
the concentration range of quencher used and the
quenching constants are presented in Table 3.
Iodide is an anion and does not penetrate the
hydrophobic region of the bilayer; TEMPO dissolves
in water and in the bilayer interface and its partition
in DPPC and DMPC is influenced by changes in
w xtemperature 33 ; the stearic acids are almost insolu-
ble in water; however, they can be solubilized in the
hydrophobic region of the bilayer. Due to their differ-
ential localization and solubilization in the bilayer,
these quenchers were used to characterize the posi-
w xtion of DIP in the vesicles 34 .
The Stern–Volmer constants for DIP in DMPC
reported in Table 3 show that in the case of TEMPO,
an increase of around 30% occurs on going from 19
to 308C. This result is probably due to the fact that
Fig. 5. Stern–Volmer plots for DIP fluorescence quenching in
DPPC vesicles, pH 7.0 and at 308C. v, TEMPO; B, 5-DSA; ’,
12-DSA; and I, 16-DSA. Concentration of DIP, 0.6=10y5 M;
excitation at 415 nm, emission at 485 nm; concentration of DPPC
2=10y3 M.
Fig. 6. Stern–Volmer plots for DIP fluorescence quenching in
DPPC vesicles, pH 7.0 and at 508C. v, TEMPO; B, 5-DSA; ’,
12-DSA; and I, 16-DSA. Concentrations of DIP and DPPC,
excitation and emission wavelengths are the same as in Fig. 5.
Table 3
Stern–Volmer constants obtained by quenching of dipyridamole
fluorescence in phospholipid vesicles at several conditions of pH
and temperature
pH T Quencher Ksv
y1 .  .8C M
DMPC 7 19 TEMPO 254"1
5-DSA 7903"183
y30 I 1.67"0.07
TEMPO 332"3
5-DSA 4290"52
8 30 TEMPO 386"6
DPPC 4 50 TEMPO 317"4
5-DSA 3623"100
12-DSA 1690"55
7 30 TEMPO 254"2
5-DSA 9560"280
12-DSA 750"20
16-DSA 6480"150
50 TEMPO 411"4
5-DSA 3530"100
12-DSA 490"40
16-DSA 3960"50
8 30 5-DSA 9915"388
50 TEMPO 350"3
5-DSA 3884"56
 .DPPCqDPPG 11% 7 30 5-DSA 9890"360
50 TEMPO 370"4
5-DSA 3930"40
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the partitioning of TEMPO in the vesicle above the
phase transition is enhanced in agreement with ESR
w xdata 33 . Increase of pH from 7.0 to 8.0 gives an
additional 16% increase in K for TEMPO. In thesv
case of 5-DSA, it is observed that below the phase
transition, K is by a factor of 1.8 greater thansv
above the phase transition. This could be related to a
greater static quenching at lower temperatures, where
the mobilities of both fluorophore and quencher are
restricted at the bilayer interface maintaining both of
them in close proximity and facilitating the quench-
ing. This is supported by recent data on pressure
w xeffects on quenching reactions 35 . The authors found
a considerable static quenching of diphenylhexatriene
by a nitroxide radical in DMPC both in the fluid and
gel states; in the gel state, the small contribution from
dynamic quenching tends to become considerably
 .smaller around 1% of total quenching . Our data for
quenching of DIP in DPPC are quite similar: the
quenching by TEMPO is somewhat lower below the
phase transition as compared to its quenching above
 .the transition 60% lower at pH 7.0 ; the quenching
by TEMPO above the phase transition varies with
pH, being 30% greater at pH 7.0 as compared to pH
4.0, but decreasing 17% at pH 8.0 as compared to pH
7.0. For 5-DSA, which is located closer to the bilayer
surface, the quenching is reduced by a factor of
2.5–2.7 on going from 30 to 508C, showing, as for
DMPC, a more effective quenching below the lipid
transition temperature, this effect being practically
independent of pH or presence of DPPG in the
bilayer. This would imply a similar location of DIP in
the bilayer independently of pH or presence of DPPG.
In the case of 12-DSA the quenching is significantly
less effective than for 5-DSA and the effect of the
phase transition is not so strong at pH 7.0 a 50%
.reduction in K occurs on going from 30 to 508C .sv
The difference in K for 5-DSA and 12-DSA whichsv
is a factor of 12.7 at 308C and pH 7.0 reduces to a
factor of 7.2 at 508C. So, above the lipid phase
transition, 5-DSA is still more efficient than 12-DSA,
but their difference is reduced as compared to the gel
phase. Finally, data for 16-DSA suggest that although
this nitroxide has its paramagnetic fragment located
deeper in the hydrophobic bilayer interior it is almost
as efficient to quench the DIP fluorescence in the gel
 .phase its K is 68% of that for 5-DSA , and evensv
more efficient in the fluid phase ratio of K valuessv
.is 1.12 . Two possibilities arise to explain this result:
one is that due to the high probability of trans-gauche
isomerization in the membrane interior and especially
above the phase transition the paramagnetic fragment
of 16-DSA is able to approach to a close contact with
DIP located close to the bilayer interface; the second
possibility would imply that DIP resides part of the
time in the membrane hydrophobic interior, which is
not consistent with the relatively small spectral
changes observed above for DIP in the presence of
phospholipid vesicles, the small change in pK fora
the drug or the data for interaction with micelles
which imply a localization in close proximity to the
w xborder of hydrophobic and polar interface 22 . The
effect of accessibility of the paramagnetic fragment
of 16-DSA to fluorophores located in close proximity
to the membrane surface has been previously re-
w xported 36 . In this study, the authors observed a
considerable dynam ic quenching of 8-
anilinonaphthalene-1-sulfonic acid fluorescence in
DMPC vesicles above the lipid phase transition due
to the presence of nitroxide radicals. This quenching
was very efficient both for 5-DSA and 16-DSA.
Above the phase transition temperatures, the bi-
layer approaches the behavior of a non-restricted,
non-viscous solution, thus the quencher has difficulty
in reaching the fluorophore because it moves to a
different region of the bilayer. In the gel phase, the
fluorophore and the quencher find themselves in close
proximity, so the suppression becomes more probable
w x35 . Another recent paper has also reported a consid-
erable static quenching of transparinaric acid fluores-
 .cence by nitroxides 5- and 16-DSA in DPPC bilay-
w xers, especially below the lipid phase transition 37 .
In the bilayer, the quencher molecules are not dis-
tributed homogeneously relative to the position of the
fluorophore. This behavior is observed in Table 3 for
the stearic acid nitroxides, but for TEMPO, the effect
is different: in this case there is an increase in
quenching above the phase transition. This would be
consistent with a higher solubilization of the nitrox-
ide in the bilayer and more effective quenching by
enhancing the accessibility of the drug to the quencher
w x33 . At the moment it is not possible to discriminate
quantitatively the contributions of static and dynamic
quenching in our results for DIP.
The effect of different positional isomers of stearic
acid nitroxides is demonstrated in the above experi-
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ments. The K values decrease following the se-sv
quence 5-DSA)16-DSA)12-DSA)TEMPO be-
low the phase transition temperature, but this se-
quence may be altered at a temperature above the
phase transition and the new order may be described
as follows: 5-DSA;16-DSA)12-DSA;TEMPO
) Iy. This result suggests that DIP is localized closer
to the paramagnetic fragment of 5-DSA. The increase
in DIP solubility due to protonation is not sufficient
w xto overcome the hydrophobicity of the molecule 22 .
3.5. Fluorescence quenching of RA25 emission
In Table 4, data are presented on the quenching of
RA25 fluorescence emission; they suggest a different
localization of this derivative as compared to DIP.
RA25 is more hydrophilic and accessible to the water
w xsolvent 20 . The results obtained for the quenching
by 5-DSA are significantly reduced and suggest that
RA25 molecules may be located more superficially
closer to the polar heads in the region of the struc-
tured water. This behavior is similar to that observed
w xfor RA25 in micellar systems 20 . Quenching with
TEMPO also suggests a more superficial external
location for RA25 in the bilayer.
3.6. Biological acti˝ity
w xIn the work of Von Gerlach et al. 17 , over one
hundred dipyridamole derivatives were studied with
regard to their inhibitory activity upon adenosine and
phosphate ions transport in red blood cells. It has
been shown that DIP has a strong inhibitory effect on
both processes, while RA25 has no effect at all.
These results were only qualitative since no quantita-
Table 4
Stern–Volmer constants obtained by quenching RA25 in phos-
pholipid vesicles at several conditions of pH and at 508C
pH Quencher Ksv
y1 .M
DPPC 4 TEMPO 152"3
5-DSA 434"39
7 TEMPO 180"1
5-DSA 343"17
8 5-DSA 269"28
tive values of defined parameters were measured.
w xLater, in the work by Ramu and Ramu 18 , an
attempt to correlate the chemical structure with the
biological activity was performed by monitoring the
circumvention of adriamycin resistance in cells by
dipyridamole and a considerable number of DIP ana-
logues. The result of this study was the assumption
that the pyrimido-pyrimidine nucleus is not responsi-
ble for the biological effect by itself, but besides this
structural element, the need for substituents was
demonstrated. For instance, the pyridine substituents
seemed to be relevant. Since the work was based on
drug effects upon cells, precise quantitative data were
also difficult to obtain. Recently, we have studied
another important biological effect of DIP, namely its
antioxidant effect regarding oxidation of mitochon-
w xdria by iron ions 19 . In this work, we showed that
the inhibitory effect of DIP was very significant with
the concentration to obtain 50% inhibition of 1 mM.
At the same time, this concentration for RA25 was by
two orders of magnitude greater, 100 mM. This result
is in agreement with data on inhibition of adenosine
and phosphate transport through red blood cells where
a strong effect was found for DIP and no effect for
RA25. In our present work, the fact that the associa-
tion constant for binding of RA25 to DPPC vesicles
is only a factor of 4 lower than that for DIP suggests
that the pyrimido-pyrimidine nucleus could be essen-
tial for the insertion of the drug in the membrane, but
that the key element for biological activity is indeed
associated to the substituents as suggested by Ramu
w xand Ramu 18 .
4. Conclusions
In the present work, the interaction of dipyri-
damole and RA25 with phospholipid vesicles was
investigated through the use of fluorescence.
A value of association constants of 1150 My1 was
obtained for DPPC and 950 My1 for DMPC above
the lipid transition temperature at pH 7.0. In the case
of DPPC, the association constant below the transi-
tion temperature decreases by a factor of around 2
 .1.8–2.2 . So, the binding is more effective in the
liquid crystalline lipid phase. Also, the neutral drug
has an association constant higher as compared to the
 .protonated drug a factor of 3 .
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Quenching experiments are suggestive of the local-
ization of the drug in the hydrophobic medium close
to the phospholipid polar headgroup. Interestingly,
the behavior of TEMPO and 5-DSA is quite different,
suggesting the possibility of very effective static
quenching for 5-DSA below the transition tempera-
ture, while in the case of TEMPO, a significant
contribution to quenching could be due to a dynamic
mechanism.
Results with the DIP derivative RA25 are in close
agreement with the observations in micelles: much
 y1.lower association constant 295 M independent of
pH and more superficial localization with great ac-
cessibility to the aqueous phase. So, it can be as-
sumed that the DIP interaction with phospholipid
vesicles depends on the nature of the side substituents
and the state of protonation of the tertiary nitrogens.
The side substituents, which define the hydrophobic-
ity of the molecule, are responsible for the drug
location in these systems. Our data also indicate that
the pyrimido-pyrimidine nucleus might be important
for the insertion of DIP and derivatives in the mem-
brane since despite the significant difference in bio-
logical activity of DIP and RA25 more than two
w x.orders of magnitude 19 only a 4-fold reduction in
binding constant to DPPC is observed.
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